One of 10 groups funded by the U.S. National Institutes of Health through the flagship Martin Delaney Collaboratories program for HIV cure research, REACH brings together an experienced and cutting-edge team of investigators

Although great strides have been made in treatment of HIV with antiretroviral therapy (ART), the need for an HIV cure remains compelling. The central theme of the REACH Collaboratory is that cellular immune responses (NK and T cells), combined with next-generation virus-neutralizing biologics, can be harnessed to achieve durable remission and eradication of HIV. Our approach centers around three Research Foci that emphasize back-to-basics science but that connect this with discovery-to-translational pipelines directed toward both HIV remission and eradication. We are prioritizing the study of diverse populations, including African populations and women, to advance a cure for all.